Waterloo Capital L.P. Buys 59 Shares of STERIS plc (NYSE:STE)

Waterloo Capital L.P. boosted its position in shares of STERIS plc (NYSE:STE) by 3.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,916 shares of the medical equipment provider’s stock after buying an additional 59 shares during the quarter. Waterloo Capital L.P.’s holdings in STERIS were worth $421,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of STERIS during the fourth quarter valued at $220,954,000. Massachusetts Financial Services Co. MA lifted its position in STERIS by 13.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after purchasing an additional 778,613 shares during the period. APG Asset Management US Inc. bought a new position in shares of STERIS in the 4th quarter valued at about $74,963,000. Sustainable Growth Advisers LP boosted its stake in shares of STERIS by 23.5% in the 1st quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after purchasing an additional 282,387 shares during the last quarter. Finally, Impax Asset Management Group plc grew its position in shares of STERIS by 29.7% during the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock worth $251,663,000 after buying an additional 263,383 shares during the period. 94.69% of the stock is currently owned by institutional investors.

Insider Activity at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the sale, the director now owns 582 shares of the company’s stock, valued at $139,493.76. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

STERIS Stock Up 0.5 %

NYSE:STE opened at $239.46 on Friday. The stock has a market cap of $23.62 billion, a price-to-earnings ratio of 62.69 and a beta of 0.83. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. The stock has a 50-day moving average price of $235.95 and a two-hundred day moving average price of $225.52. STERIS plc has a 1 year low of $195.47 and a 1 year high of $248.24.

STERIS (NYSE:STE) last posted its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. STERIS had a return on equity of 13.85% and a net margin of 7.36%. STERIS’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.00 EPS. As a group, equities analysts expect that STERIS plc will post 9.05 earnings per share for the current year.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, September 5th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.95%. This is a positive change from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, September 5th. STERIS’s dividend payout ratio (DPR) is presently 59.69%.

Analyst Ratings Changes

STE has been the topic of a number of recent research reports. Stephens reaffirmed an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. StockNews.com upgraded STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. KeyCorp raised their target price on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $246.00.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.